Save the Date for our Annual NAAF Patient Conference - Reaching New Summits Together - June 30 - July 2, 2023 in Denver, Colorado!
Participants must be 6 to 11 years old with a diagnosis of severe alopecia areata
The purpose of this study is to collect data to support the appropriate dose of the study medicine for future studies in children 6 to 11 years of age with severe alopecia areata. There will be about 12 to 15 participants taking part in this study.
Your child may qualify to participate in this study if they: *
*Other eligibility criteria also apply.
Participants will have three office visits, one at screening, one at the beginning of treatment, and one at the end of treatment or early end of the study. Participants will be asked to take one capsule of the study medicine (dissolved in water) each day, in the morning, for one week.
Participants will be in this study for approximately two months, including a 28-day screening period, 7- day treatment period, and a 35-42 day follow-up period. Participants will be contacted by phone by their trial doctor or the trial nurse at least four times between their first and last dose of trial medicine.
Participants are free to stop being in this study at any time and for any reason. Your participation in this study is at no cost to you.
This study is taking place at research sites throughout the United States. For more information on the study, visit: www.PfizerPedsAlopeciaAreatastudy.com or contact a study site listed below.
561 Saxony Place Suite 102
Encinitas CA 92024
Contact: Oralia Cruz
7910 North Shadeland Ave
Indianapolis, IN 46250
Contact: Elissa O’Malley
Phone: 317-516-5030 ext 193